CN109688983A - Medicine released biological degradability bracket - Google Patents

Medicine released biological degradability bracket Download PDF

Info

Publication number
CN109688983A
CN109688983A CN201680088648.6A CN201680088648A CN109688983A CN 109688983 A CN109688983 A CN 109688983A CN 201680088648 A CN201680088648 A CN 201680088648A CN 109688983 A CN109688983 A CN 109688983A
Authority
CN
China
Prior art keywords
structural body
support structural
main part
bracket
printing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201680088648.6A
Other languages
Chinese (zh)
Other versions
CN109688983B (en
Inventor
朴宪国
文锺必
张峰硕
尹镐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MI Tech Co Ltd
Original Assignee
MI Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MI Tech Co Ltd filed Critical MI Tech Co Ltd
Publication of CN109688983A publication Critical patent/CN109688983A/en
Application granted granted Critical
Publication of CN109688983B publication Critical patent/CN109688983B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/852—Two or more distinct overlapping stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/148—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C64/00—Additive manufacturing, i.e. manufacturing of three-dimensional [3D] objects by additive deposition, additive agglomeration or additive layering, e.g. by 3D printing, stereolithography or selective laser sintering
    • B29C64/10—Processes of additive manufacturing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C67/00—Shaping techniques not covered by groups B29C39/00 - B29C65/00, B29C70/00 or B29C73/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B33—ADDITIVE MANUFACTURING TECHNOLOGY
    • B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y70/00—Materials specially adapted for additive manufacturing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B33—ADDITIVE MANUFACTURING TECHNOLOGY
    • B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y80/00—Products made by additive manufacturing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0014—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof using shape memory or superelastic materials, e.g. nitinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2220/00—Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2220/0025—Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2220/00—Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2220/0025—Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements
    • A61F2220/0058—Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements soldered or brazed or welded
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2240/00—Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2240/001—Designing or manufacturing processes
    • A61F2240/002—Designing or making customized prostheses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
    • A61F2250/003—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in adsorbability or resorbability, i.e. in adsorption or resorption time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
    • A61F2250/0039—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in diameter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/006—Additional features; Implant or prostheses properties not otherwise provided for modular
    • A61F2250/0063—Nested prosthetic parts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
    • A61F2250/0068—Means for introducing or releasing pharmaceutical products into the body the pharmaceutical product being in a reservoir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0096—Markers and sensors for detecting a position or changes of a position of an implant, e.g. RF sensors, ultrasound markers
    • A61F2250/0098—Markers and sensors for detecting a position or changes of a position of an implant, e.g. RF sensors, ultrasound markers radio-opaque, e.g. radio-opaque markers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow
    • A61L2300/604—Biodegradation

Abstract

The present invention relates to a kind of medicine released biological degradability brackets, it include: first support structural body, it is braided on fixture by the wire of marmem material and is formed by specific pattern, and multiple cells (Cell) is had according to the silk cross-modality on braiding structure and is configured as hollow tubular；And second support structural body, it is the 3D printing object for carrying out 3D printing using the printing material comprising biodegradation high molecular and drug and being formed, the 3D printing object has multiple cells according to the silk cross-modality in print structure and is configured as hollow tubular, and the second support structural body is arranged to cover the outer peripheral surface of the first support structural body or the outer peripheral surface of the second support structural body is covered by the first support structural body.

Description

Medicine released biological degradability bracket
Technical field
The present invention relates to a kind of medicine released biological degradability brackets.
Background technique
Bracket (Stent) generally after being arranged at the diseased region inner cavity that such as generation is narrow, passes through in set position The shape memory characteristic of wire realizes structural expansion, therefore intracavitary length inside by the auxiliary of additional extension element Time maintains predetermined form, and restores the intracavity diameter that narrows due to narrow, and also act as ensure movable passageway so as to The substance movement of the inner cavity extended can be gone on smoothly.
Although more going a step further since then recently, as described above, bracket will restore intracavity diameter as basic object Research and development can be arranged on the surface of additional coating film or the silk in composition support skeleton in bracket outer peripheral surface and form coat, So as to so that the bracket release that inner cavity is arranged in is included in the bracket of the drug of coating film or coat.
Bracket discharges drug while restoring intracavity diameter, therefore in the lesion site that standoff inner cavity is arranged It can continue the drug therapy of progress scheduled period, so as to provide anticancer or antibacterial and other effects.
About this, in order to store drug in scaffolding thread structure, and make drug in setting bracket and by the predetermined time The existing literature of the related art discharged afterwards has: Korean Patent Publication No. 10-1467102 " drug storage use Multilayer structure making and include the structural body medicine released support " (hereinafter, being referred to as " prior art ").
But for medicine released support existing for the prior art etc., due to using using wire as base Frame and the supporting structure body for preparing carry out the mode for the coating film that coating processing operation contains extra drug to additional application, because This is difficult to accurately design substantive coating zone, it is described substance coating zone in order to by release drug by drug effect extremely Lesion and be equipped with, and there is release amount of medicine, rate of release and release time etc. to be slightly not enough to mention in effect to lesion The problem of for abundant effect.
Also, for existing biodegradation high molecular constitutes the medicine released support of main silk skeleton, though It is so capable of providing the release amount of medicine appropriate of effect to diseased region, but the bracket of wire pedestal can not be sufficiently provided Intracavity diameter recovery effects provided by structure are horizontal, and adequately prevent mobility from setting position with that cannot provide To be easy to the problems such as being detached from.
Summary of the invention
Technical problem
The present invention is found out to solve the above-mentioned problems, and the purpose of the present invention is to provide following brackets: basic tool Have and the inner cavity scalability of position adequately is set from bracket and prevents mobility level, and then passes through medicine in diseased region offer Fine design can be carried out to drug delivery area when the therapeutic effect of object release and set, and the release of drug The drug releases forms such as amount, rate of release and release time can provide effective therapeutic effect due to supporting structure.
Technical solution
To achieve the goals above, the medicine released biological degradability bracket packet of first embodiment according to the present invention Include: first support structural body is braided by specific pattern on fixture by the wire of marmem material and is formed, and There is multiple cells (Cell) according to the silk cross-modality on braiding structure and be configured as hollow tubular；And second Supporting structure body is that the 3D for carrying out 3D printing using the printing material comprising biodegradation high molecular and drug and being formed is beaten Object is printed, the 3D printing object has multiple cells according to the silk cross-modality in print structure and is configured as hollow cylinder Shape, and the second support structural body is arranged to cover the outer peripheral surface of the first support structural body or the second support The outer peripheral surface of structural body is covered by the first support structural body.
Herein, the second support structural body can after 3D printing by using be mixed with biodegradation high molecular with And the coating processing process on the surface of the application of mixture of drug, the coat comprising drug is formed on surface.
And it is possible to make biological in order to be equipped in the printing material that the second support structural body utilizes by 3D printing Degradable polymer and the painting utilized to be equipped with the coat of the stacking coated on second support structural body surface More than one difference in the mutual type of biodegradation high molecular in mixture and composition ratio is covered, so that in order to pass through 3D printing be equipped with the second support structural body and in the printing material that utilizes biodegradation high molecular biodegradation period Than the coat for being coated on second support structural body surface being laminated and in the application of mixture being utilized to be equipped with The biodegradation period of biodegradation high molecular is long.
Also, in order to by 3D printing be equipped in the printing material that the second support structural body utilizes drug in order to It is equipped with stacking and is coated on the coat on second support structural body surface and drug can be in the application of mixture that utilizes It is equipped with using the drug of identical type.
Also, the first support structural body includes: the first main part, is formed as hollow tubular；First expansion tube department, One end of first main part is formed with the diameter compared to first main part extension；And second expansion tube department, described The other end of first main part is formed with the diameter compared to first main part extension, and the second support structural body is provided as Length with the length for being less than or equal to first main part, and can be set to cover the outer of first main part The outer peripheral surface of circumferential surface or the second support structural body is covered by the main part.
Herein, the medicine released biological degradability bracket further include: multiple radiopacity label are arranged in institute The multiple regions on first support structural body are stated, to ensure that the visuality of bracket in vivo is arranged, the multiple ray is impermeable Property label in more than two radiopacities label of the both ends side for being set to first main part can be by It is set as the both ends of the second support structural body being fixedly attached to the form of first main part.
In addition, to achieve the goals above, the medicine released biological degradability branch of second embodiment according to the present invention Frame includes: the first main part, is formed as hollow tubular；First expansion tube department, in one end of first main part to compare institute The diameter for stating the extension of the first main part is formed；And second expansion tube department, first main part the other end compared to described The diameter of first main part extension is formed, and the third supporting structure body includes: the second main part, is formed as hollow tubular； Third expansion tube department is formed in one end of second main part with the diameter compared to second main part extension；And the 4th Expansion tube department is formed in the other end of second main part with the diameter compared to second main part extension, described second Frame structural body is provided as with the length less than or equal to first main part and the length of second main part, and It is inserted into and is set between first main part and second main part.
Herein, the second support structural body can after 3D printing by using be mixed with biodegradation high molecular with And the coating processing process on the surface of the application of mixture of drug, the coat comprising drug is formed on surface.
Also, in order to be equipped with biological degradability in the printing material that the second support structural body utilizes by 3D printing Macromolecule is mixed in order to be equipped with the coating that stacking is coated on the coat on second support structural body surface and utilizes More than one in object in the mutual type of biodegradation high molecular and composition ratio is different, so that in order to pass through 3D printing Be equipped with the second support structural body and in the printing material that utilizes biodegradation high molecular biodegradation period ratio in order to The coat for being coated on second support structural body surface is laminated for outfit and biology drops in the application of mixture being utilized The high molecular biodegradation period of solution property is long.
Also, in order to by 3D printing be equipped in the printing material that the second support structural body utilizes drug in order to It is equipped with stacking and is coated on the coat on second support structural body surface and drug can be in the application of mixture that utilizes It is equipped with using the drug of identical type.
Also, the first support structural body includes: the first main part, is formed as hollow tubular；First expansion tube department, One end of first main part is formed with the diameter compared to first main part extension；And second expansion tube department, described The other end of first main part is formed with the diameter compared to first main part extension, and the third supporting structure body includes: Second main part is formed as hollow tubular；Third expansion tube department, in one end of second main part with main compared to described second The diameter of body portion extension is formed；And the 4th expansion tube department, in the other end of second main part to compare second main body The diameter of portion's extension is formed, the second support structural body can be provided as having less than or equal to first main part and The length of the length of second main part, and be inserted into be set to first main part and second main part it Between.
Herein, in the side of first support structural body and third supporting structure body, by first expansion tube department and third The bound fraction that expansion tube department and second expansion tube department and the 4th expansion tube department can be formed as one respectively is matched by each region Standby is more than one, and the second support structure is inserted between first support structural body and third supporting structure body Body.
Invention effect
According to the present invention it is possible to play following effect.
First, by by the first support structural body of wire pedestal and pass through 3D printing be equipped with biological degradability high score The second support structural body of subbase frame is integrated and forms an intact stent, so as to provide simultaneously by first support The function of the intracavity diameter level of the recovery lesion site of the extension of structural body and drug by second support structural body The function of the lesion of the treatment lesion site of release.
Second, due to the second support structural body for drug release be by using include biodegradation high molecular with And the printing material of drug executes 3D printing and realizes, therefore drug is evenly distributed over and is immersed in and is equivalent to 3D printing object Second support structural body inside, so as to effectively provide the lesions treatment effect by drug release.
Third, the second support structural body configured and to additional execution 3D printing carry out coating processing process and are tying The external side of structure, which forms medicine released coating film, can also will constitute second to can not only provide a greater amount of drugs Biodegradation period difference between the biodegradation high molecular of frame structural body and the biodegradation high molecular for forming coating film Change, so as to so that drug can carry out the orderly release with the time difference.
4th, most preferably, the length horizontal of second support structural body and execution are using wire as the first support of pedestal The length horizontal of the intermediate host of the function of the substantive recovery intracavity diameter level of structural body or third supporting structure body It is corresponding or smaller, so that drug release is executed in the expansion tube department side arranged for providing the preventing mobility of bracket, because This can be minimized the unnecessary region that cannot accurately act on lesion.
Detailed description of the invention
Fig. 1 is the solid for showing the structure of medicine released biological degradability bracket of first embodiment according to the present invention Figure.
Fig. 2 is the decomposition for showing the structure of medicine released biological degradability bracket of first embodiment according to the present invention Perspective view.
Fig. 3 be for illustrate the medicine released biological degradability bracket of first embodiment according to the present invention according to branch The sectional view of the cross-section structure of interconnection form between frame structural body.
Fig. 4 is second for illustrating the medicine released biological degradability bracket of first embodiment according to the present invention Frame structural body is cutd open the cross-section structure according to the interconnection form between supporting structure body after coating processing process Face figure.
Fig. 5 is the decomposition for showing the structure of medicine released biological degradability bracket of second embodiment according to the present invention Perspective view.
Fig. 6 be for illustrate the medicine released biological degradability bracket of second embodiment according to the present invention according to branch The sectional view of the cross-section structure of interconnection form between frame structural body.
Fig. 7 is the second support knot for showing the medicine released biological degradability bracket of second embodiment according to the present invention Cross-section structure according to interconnection form supporting structure body between of structure body in the state of by coating processing process Sectional view.
Fig. 8 is the figure for showing the medicine released biological degradability bracket of second embodiment according to the present invention.
<symbol description>
100,400,500: medicine released biological degradability bracket
110,410,510: first support structural body
111,511: the first main part
112,512: the first expansion tube department
113,513: the second expansion tube department
120,420,520: second support structural body
M1: biodegradation high molecular in printing material
D1: drug in printing material
425,525: coat
M2: biodegradation high molecular in application of mixture
D2: drug in application of mixture
130,540: radiopacity label
530: third supporting structure body
531: the second main parts
532: third expansion tube department
533: the four expansion tube departments
Specific embodiment
For the preferred embodiment of the present invention, be described in more details referring to attached drawing, in order to illustrate terseness, it is right Known technology part will be omitted or be compressed.
< for the constituent element of medicine released biological degradability bracket according to first embodiment and the explanation of structure >
It is illustrated referring to figs. 1 to Fig. 4, the medicine released biological degradability bracket of first embodiment according to the present invention 100 include: first support structural body 110；Second support structural body 120；And radiopacity label 130.
First support structural body 110 is equivalent to first group of bracket for being used to repair intracavity diameter of following hollow cylindrical Part: it is woven and the bending up and down of the wire 110W prepared with marmem in fixture with predetermined pattern, thus root There are multiple cell 110C (Cell) according to the silk cross-modality of braiding structure.
This first support structural body 110 can be prepared by more than one wire 110W, utilize two In the case that above wire 110W forms braiding structure, a part of the main structure for preferably respectively constituting each silk into Row is distinguished, to be divided into first part and second part, and it is attached by mutual braiding structure.
At this point, first support structural body 110 is according to the position and diameter level in overall structure and including the first main body Portion 111, the first expansion tube department 112 and the second expansion tube department 113.
Firstly, the first main part 111 is to restore branch erection by substantive execute of extension of first support structural body 110 The bracket central main part of intracavity diameter horizontal functional in seated position, and be formed as hollow tubular.
Secondly, the first expansion tube department 112 is following bracket one end airfoil section: from one end of the first main part 111 with First main part 111 compares the diameter that more extends and extends and is formed, thus when bracket is arranged offer prevent detachment and It prevents ambulant.
Finally, the second expansion tube department 113 is following bracket other end airfoil section: from the other end of the first main part 111 Extended with the diameter more extended compared with the first main part 111 and formed, so that providing when bracket is arranged prevents detachment And prevent mobility.
Second support structural body 120 is held using the printing material for including biodegradation high molecular M1 and drug D1 Row 3D printing is to have multiple cell 120C (Cell) by the cross shaped head of the silk 120W in print structure and arrange It is for providing second group of bracket to the therapeutic effect of lesion by drug release for the 3D printing object with cylindrical shape Part.
Accordingly, the integral skeleton structure as the second support structural body 120 of 3D printing product is with biological degradability high score Son is constituted for pedestal, and inside it, the drug being contained in printing material is uniformly distributed integrally.
It is possible, firstly, to the biodegradation high molecular M1 being contained in inside printing material be configurable to polyethylene, polyester, Polypropylene, polyvinyl chloride, expanded PTFE (ePTFE), polyethylene naphthalate, polybutylene naphthalate, Polytrimethylene naphthalate, trimethylene naphthalate, polytetrafluoroethylene (PTFE), polyurethane, polyureas, silicon, polyamide, The fluorinated ethylene propylene such as polyimides, multiple carbonate, polyacetals, polyether-ether-ketone, natural rubber, polyethers, are gathered at fluorinated ethylene propylene Vinyl acetate, polystyrene, poly- (ethylene glycol terephthalate), naphthalene, dicarboxylic acid derivatives etc. are by complete halogenation or portion Divide the polyethers of halogenation, polyvinyl alcohol, polyethylene glycol, polylactic acid, polyglycolide, polyethylene oxide, polydioxanone, gather Acid lactone, polyphosphazene, polyanhydride, polyaminoacid, acetylbutyrylcellulose, cellulose triacetate, polyacrylate, polyacrylamide One or a combination thereof in amine, polysiloxanes, polyvinylpyrrolidone, terylene and its copolymer.
Specifically, biodegradation high molecular M1 can be polyester copolymer, styrene-butadiene copolymer, the poly- ammonia of silicon Ester copolymer etc..
Also, according to implementation, biodegradation high molecular M1 can be poly- (L- lactide) (PLLA), the poly- (friendship of D, L- third Ester) (PLA), poly- (glycolide) (PGA), poly- (L- lactide-co-d, L- lactide) (PLLA/PLA), poly- (L- lactide-co- Glycolide) (PLLA/PGA), poly- (d,L-lactide-co-glycolide) (PLA/PGA), poly- (lactide-co-trimethyl carbonic acid Ester) (PGA/PTMC), polydioxanone (PDS), pla-pcl (polycaprolactone, PCL), poly butyric ester (PHBT), poly- (phosphonitrile), poly- (D, L- lactide-co-caprolactone) (PLA/PCL), poly- (glycolide-co- caprolactone) (PGA/ PCL), one or a combination thereof in poly- (phosphate) and its copolymer.
It is then possible to which the drug D1 being contained in printing material can be provided as anticancer agent (taxol (paclitaxel), adriamycin (doxorubicin), gemcitabine (gemcitabin), 5 FU 5 fluorouracil (5-FU), albumin Mating type taxol (abraxane), vincaleukoblastinum (vinblastin), Sorafenib (sorafenib), Cetuximab, her horse For Buddhist nun, Gefitinib, Tarceva, Sutent, Herceptin, capecitabine etc.), antibiotic (cefotaxime (cefotaxime), vancomycin, tetracycline, beta-lactam antibiotic, polymyxins, sulfamido, pyrimethamine, Li Fu Flat, quinolone, aminoglycoside etc.), immunosuppressor (such as sirolimus (sirolimus), Zuo Tamosi (zotarolimus), All limus classes such as everolimus (everolimus)), one in anti-platelet agents (Cilostazol (cilostazol)) or Person's a combination thereof.
Also, drug D is not limited to this, and can be equipped with a variety ofly, for example, adrenaline excitant, kidney can be provided as Upper gland corticosteroid, adrenal cortex reaction suppressor, ethyl alcohol obstruction, aldosterone antagonists, amino acids and protein, Ammonia detoxicant (ammonia detoxicants), protein assimilating agent, the medicament for regaining one's strength, analgesic, androgen agent, Anaesthetic, without appetite compound, the medicament for nerve without appetite disease patient, antagonist, anterior pituitary active body and anti- Answer inhibitor, pest repellant, antiadrenergic drug functional agent, anti-allergic agent, amebicide agent, antiandrogen medicament, anti-anemia action Medicament, antianxiety medicament, anti-joint medicament, antasthmatic agent, anti-atherogenic curing agent, antibacterial agent, resists antianginal agent Cholelith (anticholelithic) medicament, anti-gall-stone formation medicament, cholinolytic agonist, anticoagulant, anticoccidial (anticoccidal) medicament, anticonvulsant, antidepressant, antidiabetic, antidiuretic, antidote, antidyskinetic agent, Anti- vomitory, antiepileptic, antiestrogenic agent, antifibrinolysis agonist, antifungal preparation, antiglaucoma agent, anti-blood Friendly disease medicament, anticoagulant factor, antihaemorrhagics agent, antihistaminic, the agent of lipidemia disease, hyperlipoproteinemia Remedies, anti-high blood It presses agent, hypotension agent, anti-keratinization medicament, antimicrobial agent, anti-migraine agent, inhibition of cell proliferation, antimycotic agent, resist Antineoplastic agents, anticancer the synergy of (anti-cancer) complementarity (potentiating) medicament, anti-Neutrophilic granulocytopenia medicament, Anti- besetment medicament, antiparasitic, anti-Parkinson's disease medicine, anti-pulmonary cyst type medicament, anti-proliferative agent, anti-hypertrophy of the prostate Medicine, antiprotozoal, antipruritic, curing psoriasis agent, antipsychotics, resisting rheumatoid disease agent, anti-schistosome medicament, anti-skin Rouge leaks medicament, spasm sedative, antithrombotic agent, antitussive, antiulcer type medicament, anti-urolithic agent, antivirotic, bone suction Receive inhibitor, bronchial dilation agent, carbonic anhydrase inhibiting substances, cardiac function depressant, heart protective agent, cardiac stimulant, the heart Dirty vascular type medicament, bile secretion promote medicament, choline medicament, choline promotor, cholinesterase deactivators, coccidiosis system Agent medicament, sedative, diagnostic assistance program, diuretics, dopamine medicament, anti-ectoparasite agent, vomiting inducer, enzyme inhibit Agent class, fibroid medicament, oxygen free radical scavenger, enterogastric peristalsis agent, glucocorticoid, sexual gland stimulation principle, is stopped estrus hormone Blood preparation, histamine H2receptor blockaders, hormone, low cholesterol disease medicament, Hypoylycemic agents, low hemostatic agent, hypotensive agent, Hmgcoa reductase inhibitor, immune amount medicament, immunomodulator, immune regulator, tartaric acid agent, lutropin release swash Plain (LHRH) antagonist, Luteolin medicament, mucopolysaccharide hydrolysis-type mucosa protective agent, mydriatic, nasal congestion remover, nerve pine Relaxation agent, neuromuscular blocking agents, neuroprotective agent, aspartate antagonist, non-hormone steroid derivatives, uterotonics One or a combination thereof in agent, plasminogen activator.
As previously mentioned, can with multiple combinations prepare printing material according to pass through second support structural body 120 to lesion The purpose of therapeutic effect by drug is provided, it can be by the composition content ratio of drug, for determining drug release period Type and composition content ratio of biodegradation high molecular etc. carry out a variety of design variations and implement.
The printing material prepared as described above most preferably is prepared as only including biodegradation high molecular and medicine Object to be applied to the 3D printer that melting is laminated into type (FDM, Fused Deposition Modeling) mode, and is being incited somebody to action After printing bed (build plate) is arranged as cylindrical shape, it is rotated on the basis of when executing 3D printing by axis, to make The printing material for being heated and melting is sprayed from nozzle, so that eject position is with printing bed during printing bed is cured Rotation and continuous deformation, therefore constitute hollow cylinder-shaped second support structural body 120.
But, however it is not limited to this can also utilize and wrap together other than using biodegradation high molecular and drug The printing material for heat or UV polymerization monomer and heat or UV polymerization initiator etc. is included, and using using at digital light Manage device (DLP, Digital Light Processing), Stereo Lithography Apparatus (SLA, Stereolithography Apparatus), the modes such as selective laser sintering (SLS, Selective Laser Sintering) or Poly-Jet 3D printer executes 3D printing, to print hollow cylinder-shaped second support structural body 120.
As described above in the second support structural body 120 based on 3D printing, it is evenly distributed in the inside of total The drug D1 of proper level, since the composition contents level of printing material and the design of type can be changed a variety ofly, It is easy to that position and purpose is arranged and is equipped with corresponding medicine released support structural body according to bracket.
That is, configuring the second support structural body 120 with biological degradability and medicine releasability by 3D printing, make Obtaining designer not only can be arranged position and purpose according to bracket, easily to required release drug, drug release shape State and diameter and length equal-specification level are adapted to, so that drug can equably divide via entire supporting structure Cloth.
Also, in the overall structure of medicine released biological degradability bracket 100, pass through second support structural body 120 Minimize the distributed degrees of the wires such as first support structural body 110, to further improve as setting in body Bracket biocompatibility it is horizontal.
Company as shown in Fig. 3 (a) and Fig. 1, between this first support structural body 110 and second support structural body 120 Connecing form can be that the outer of second support structural body 120 is covered by first support structural body 110 according to the first connection prominent form Circumferential surface, so that drug D1 be made to pass through the silk 120W's for constituting second support structural body 120 from the inside of first support structural body 110 The biodegrade of biodegradation high molecular M1 and be discharged.
Also, as shown in Fig. 3 (b), according to the between first support structural body 110 ' and second support structural body 120 ' Two connection forms, can be set to cover the outer peripheral surface of first support structural body 110 by second support structural body 120, to make Drug D1 from the outside of first support structural body 110 by constituting the biology of the silk 120W of second support structural body 120 by dropping The biodegrade of solution property macromolecule M1 and be discharged.
More specifically, it is preferable to which ground, configures the phase compared with the first main part 111 for the length of second support structural body 120 With perhaps shorter length 120D to cover the outer peripheral surface of the first main part 111 or cover outer peripheral surface by main part 111.
In other words, as shown in Fig. 2, the length horizontal 120D of second support structural body 120 is provided as and the first main part 111 length horizontal 111D is compared, and is arranged as in identical or smaller in similar level level.
Since it takes into account that the practical recovery generation lesion that executes leads to the first master of the intracavity diameter horizontal functional to narrow Body portion 111 is inevitable directly to be contacted with diseased region, therefore drug is made not have effect aspect unnecessary portion and act on.
In other words, by the way that the length horizontal 120D of second support 120 to be provided as to the length phase with the first main part 111 Than, it is identical corresponding with the first main part 111 like or similar horizontal smaller level, thus in lesion peripheral portion It is arranged when the setting of position.
Individual coating processing is carried out in addition, can add by the second support structural body 420,420 ' that 3D printing is equipped with Process.
Second support structural body 420,420 ' can be mixed with biodegradation high molecular M2 by utilizing after 3D printing And the coating processing process on the surface of the application of mixture of drug D2 surface formed the coat 425 containing drug, 425’。
Here, as shown in figure 4, the formation form of coat is divided into two kinds of forms, firstly, having the first coating form Medicine released biological degradability bracket 400 cross-section structure such as Fig. 4 (a) shown in.
With first coating form medicine released biological degradability bracket 400 second support structural body 420 into It is sprayed after row 3D printing by atomizing mixture or the dipping process in application of mixture, whole as shown in Fig. 4 (a) A second support structural body 420 forms membranaceous coat 425.
Moreover, as a result, the cell structure of second support structural body 420 due to formed film coat 425 and by Closing, so that tubulose be integrally formed, is provided in the inside of the membranaceous coat 425 of second support structural body 420 or outside First support structural body 410.
The second support structural body 420 ' of medicine released biological degradability bracket 400 ' with the second coating form exists It is sprayed by atomizing application of mixture or the dipping process in application of mixture after carrying out 3D printing, as shown in Fig. 4 (b) Outer side surface of the ground on the silk structure 420W ' for forming 420 ' skeleton of second support structural body forms the painting of the form of stacking coating Coating 425 '.
And as a result, the cell structure of second support structural body 420 ' can only narrow, without because of coat 425 ' are closed, and due to silk structure, first support structural body 410 ' is set to the second support structure for being formed with coat 425 ' The inside or outside of body 420 '.
The coat 425,425 ' that can be equipped with by above-mentioned variform utilizes and is mixed with biodegradation high molecular The application of mixture of M2 and drug D2 and be equipped with, the biodegradation high molecular M2 and drug for this application of mixture The embodiment of D2 is identical as the embodiment of biodegradation high molecular M1 and drug D1 for printing material in preceding explanation.
It is to make to pass through coat in the coat 425,425 ' that second support structural body 420,420 ' is additionally formed 425,425 ' biodegradation high molecular M2 biodegradable drug D2 release by second support structural body 420, It is preferential before the biodegradable drug D1 release of 420 ' biodegradation high molecular M1 to carry out.
Thus, it is preferable that in order to be equipped with the printing material that second support structural body 420,420 ' uses by 3D printing The biodegradable sexual cycle of interior macromolecule M1 is longer than to be equipped with the painting for being laminated in second support structural body 420,420 ' surfaces Coating 425,425 ' and the biodegradation high molecular M2 in the application of mixture that uses, should differently from each other design biological drop At least one of in the high molecular type of solution property and composition ratio,.
Also, it is configured in the printing material that second support structural body 420,420 ' uses to be equipped with by 3D printing Drug D1 and in order to be provided in second support structural body 420,420 ' surfaces stacking coating coat 425,425 ' and use Drug in application of mixture should be provided as the drug of identical type.
As a result, can once be dropped by the biology of the biodegradation high molecular M2 according to coat 425,425 ' The drug D2 of solution discharges and acts on drug in lesion first, then secondaryly by according to second support after the predetermined time The biodegrade of the biodegradation high molecular M1 of structural body 420,420 ' and discharge drug D1.
According to embodiment, additional design can be carried out, to make coat 425 ' in second support structural body 420,420 ' Laminated multi-layer and formed, thus allow drug release in multiple times have the time poorly execute.
Also, according to embodiment, in order to carry out being equipped with what second support structural body 420,420 ' used by 3D printing In printing material drug D1 and in order to prepare coating be laminated in second support structural body 420,420 ' surfaces coat 425, 425 ' and drug can be provided as variety classes in the application of mixture that uses, it is secondary thus after once discharging the first drug Ground release and different second drug of the first drug, to be provided as that two or more drugs can be provided to lesion.
As shown in Figure 1, medicine released biological degradability of radiopacity label 130 in order to ensure setting in vivo The visuality of bracket 100 and be set to the multiple regions on first structural body 110.
Here, multiple radiopacity label 130 are to be confirmed by the inspection using rays such as x-rays in outside One kind of label of the internal position of medicine released biological degradability bracket 100, mainly executes as position mark Function, however as shown in the amplifier section of Fig. 1, a portion provides the function of connection dual-purpose radiopacity label 130 ' Energy.
In other words, as shown in the amplifier section of Fig. 1, in multiple radiopacity label 130, it is arranged in first support Two end sides of the first main part 111 of structural body 110 more than two radiopacities label 130 ' be set as by The both ends of second support structural body 120 are fixedly attached to the form on the outer peripheral surface of two end sides of the first main part 111, To be provided simultaneously as the function of position mark and by second support structural body 120 and first support structural body 110 Between connection position fixed function.
Also, medicine released biological degradability bracket 100 can be additionally equipped with according to implementation form is covered on first The inside of supporting structure body 110 or the individual overlay film (not shown) in outside.
Here, overlay film can from Teflon (Teflon), silicon, polytetrafluoroethylene (PTFE) (PTFE, Polytetrafluoroethylene), polyurethane, polyester, polypropylene, polyethylene, polyolefin, high density polyethylene (HDPE) (HDPE, High Density Polyethylene) and expanded PTFE (ePTFE, expanded- Polytetrafluoroethylene selection in), but can be with being not particularly limited from the well known materials range for being applied to overlay film Interior selection.
< for the constituent element of medicine released biological degradability bracket according to the second embodiment and the explanation of structure >
It is illustrated referring to Fig. 5 to Fig. 8, the medicine released biological degradability bracket of second embodiment according to the present invention 500 include: first support structural body 510；Second support structural body 520；Third supporting structure body 530；And radiopacity Label 540.
For the second embodiment of the present invention, will be carried out based on the difference with aforementioned first embodiment when being illustrated Illustrate, and repeat description will be simplified or be omitted.
Here, first of the medicine released biological degradability bracket 500 due to second embodiment according to the present invention Frame structural body 510, second support structural body 520 and radiopacity mark the Structural Characteristics of son 540 and according to described The first support structural body 510 of the medicine released biological degradability bracket 500 of the first embodiment of invention, second support structure The record of the Structural Characteristics of body 520 and radiopacity label 540 corresponds in the same manner, therefore omits specifically It is bright.
Firstly, medicine released biological degradability bracket 500 according to the second embodiment further includes one and first support Structural body 510 is in the same manner using wire as the supporting structure body of pedestal, the braiding of corresponding third supporting structure body 530 Structure and specification can be same or different with first support structural body 510.
More specifically, third supporting structure body 530 is by compiling the wire 530W of shape memory alloy material in fixture It is woven to specific pattern, to have multiple cells (Cell) due to the silk cross-modality on braiding structure and be arranged as hollow Tubular.
Accordingly, first support structural body 510 corresponds to the following extensive scaffold first assembly of intracavity diameter: by with shape Shape memory alloys be equipped with wire 510W bending up and down and woven on fixture with specific pattern, thus due to braiding structure On silk cross-modality and hollow cylinder shape with multiple cell 510C (Cell), third supporting structure body 530 are corresponding In following extensive the second component of scaffold of intracavity diameter: passing through the upper and lower curved of the wire 530W that is equipped with marmem It is bent and woven on fixture with specific pattern, to have multiple cell 530C due to the silk cross-modality on braiding structure (Cell) hollow cylinder shape.
Also, second support structural body 520 is to utilize the printing material including biodegradation high molecular M1 and drug D1 Material executes 3D printing and is equipped with multiple cell 520C (Cell) to the cross-modality due to the silk 520W in print structure, and And it is arranged as the 3D printing object with hollow cylindrical, and be by discharging drug to lesion to provide the branch of therapeutic effect Frame third component.
Also, the first embodiment being illustrated before is in the same manner, and second support structural body 520 ', 520 " passes through using mixed The application of mixture of biodegradation high molecular M2 and drug D2 after closing 3D printing and the coating processing on the surface that carries out Process and can surface formed the coat 525 ', 525 " containing drug.
Here, as shown in fig. 7, the formation form of coat is divided into two kinds of forms, firstly, having the first coating form Medicine released biological degradability bracket 500 ' cross-section structure such as Fig. 4 (a) shown in.
The second support structural body 520 ' of medicine released biological degradability bracket 500 ' with the first coating form exists Carry out 3D printing after by atomizing application of mixture spray or application of mixture in dipping process, as shown in Fig. 7 (b) Membranaceous coat 525 ' is integrally formed in second support structural body 520 '.
Also, as a result, the cell structure of second support structural body 520 due to film forming coat 525 and close, To which tubulose be integrally formed, on the basis of the membranaceous coat 525 of second support structural body 520, it is respectively disposed in medial and lateral First support structural body 510 and third supporting structure body 530.
The second support structural body 520 " of medicine released biological degradability bracket 500 " with the second coating form exists Carry out 3D printing after by atomizing application of mixture spray or application of mixture in dipping process, as shown in Fig. 7 (a) Form the coat 525 " for the outer side surface that stacking is coated on the silk structure 520W " of 520 " skeleton of second support structural body.
And as a result, the cell structure of second support structural body 520 " can only narrow, without due to coat 525 " and be closed, and on the basis of the second support structural body 520 " in silk structure to be formed with coat 525 ", inside and outside Side is respectively disposed with first support structural body 510 and third supporting structure body 530.
It is this can with variform arrange coat 525 ', 525 " using be mixed with biodegradation high molecular M2 with And drug D2 application of mixture and prepare, this biodegradation high molecular M1 and drug D1 for application of mixture and The implementation form of the biodegradation high molecular M1 and drug D1 for printing material of preceding explanation it is relevant explanation due to It is identical with content documented in the explanation to first embodiment, therefore omitted.
As shown in figure 5, due to the quantity and first embodiment of the supporting structure body for constituting entire medicine released support 500 It is not identical, therefore be connected with each other form and be also provided as being different from the first embodiment.
About this, referring to Fig. 6 and Fig. 8, it is known that be set as third supporting structure body 530 and cover first support structural body 510 outer peripheral surface, or by the outer peripheral surface of first support structural body covering third supporting structure body 530, this cambial Space between first support structural body 510 and third supporting structure body 530, is inserted with second support structural body 520.
Here, as first support structural body 510 with first embodiment by the first main part 511, the first expansion tube department 512 with And second expansion tube department 513 be equipped with, third supporting structure body 530 according in overall structure position and diameter it is horizontal, by second Main part 531, third expansion tube department 532 and the 4th expansion tube department 533 are equipped with.
First, the second main part 531 restores to prop up as substantially executing by the expansion of third supporting structure body 530 The bracket central main part for setting up the intracavity diameter horizontal functional in seated position, is formed as hollow tubular.
Then, third expansion tube department 532 is from one end of the second main part 531, compared to the second main part 531 with extension Diameter extends and is formed, so that offer prevents detachment and prevents the alar part of ambulant bracket one end when bracket is arranged Point.
Finally, the 4th expansion tube department 533 is from the other end of the second main part 531, compared to the second main part 531 to extend Diameter extend and formed, so that offer prevents detachment and prevents the wing of the ambulant bracket other end when bracket is arranged Part.
Also, second support structural body 520 is provided as having compared with the first main part 511 and the second main part 531 Identical or shorter length 520D, it is preferable that insertion is set between the first main part 511 and the second main part 531.
In other words, as shown in figure 5, the length horizontal 520D of second support structural body 520 is provided as and the first main part 511 and second main part 531 length horizontal 511D, 513D compare identical or smaller under similar level level.
Since it takes into account that practical execute the first of the function of restoring the intracavity diameter level to narrow because lesion occurs Main part 511 and the second main part 531 is inevitable directly contacts with diseased region, thus in order to make drug there is no effect in terms of Unnecessary portion and be applied in lesion.
In other words, the length horizontal 520D of second support structural body 520 is provided as and the first main part 511 and The length of two main parts 531 is compared to level smaller on equal or similar level, so that insertion is set to the first main part 511 And second between main part 531 to be arranged when bracket is arranged in perilesional position.
It is being inserted into the first main part 511 and the second main body for being provided with second support structural body 520 as described above The first expansion tube department 512 and third expansion tube department 532 and the second expansion tube department 513 and the 4th expansion tube department 533 are divided in the side in portion 531 The bound fraction C not being integrally formed is provided as more than one by each region.
Specifically, expand in the third of the first expansion tube department 512 of first support structural body 510 and third supporting structure body 530 The side of pipe portion 532, be respectively equipped with it is more than one wire 510W, 530W are connected with mutually winding, or pass through volume Outer soldering configures additional component and is formed as the bound fraction C of mutually one, this is in first support structural body As 510 the second expansion tube department 513 with the side of the 4th expansion tube department 533 of third supporting structure body 530 is also.
Here, the engaging portion being equipped in two end sides of first support structural body 510 and third supporting structure body 530 Divide C that insertion is made to be set to the second support structural body 520 between first support structural body 510 and third supporting structure body 530 It is not departed from corresponding installation space, but there is predetermined motility.
This be in order to eliminate in advance be provided with medicine released biological degradability bracket 500 according to the second embodiment Inner-cavity structure correspondingly have bending property when, due to second support structural body 520 be fixed setting and with its rupture or Therefore person, which damages, cannot have aiming at the problem that correspondence of the malformation of bending degree.
Also, the first expansion tube department 512 of first support structural body 510 and the third expansion tube department of third supporting structure body 530 The 4th of the bound fraction C of 532 sides and the second expansion tube department 513 of first support structural body 510 and third supporting structure body 530 The bound fraction C of side in the bound fraction C of 533 side of expansion tube department is unlocked when second support structural body 520 is arranged in insertion Or disintegrate and the open space for being used to be inserted into setting second support structural body 520, and later by second support structural body 520 After insertion setting, the bound fraction C for the side unlocked or disintegrated again is reverted to again be used for integrally connected from preceding shape State.
Therefore, as shown in figure 8, in multiple portions of medicine released biological degradability bracket 500 according to the second embodiment Position is provided with multiple radiopacities label 540 for executing and marking sub functions, which is for by sharp from outside With the inspection of the rays such as ray, one kind of label of the internal position of medicine released biological degradability bracket 500 is confirmed, but Preferably, it is not provided with connection dual-purpose radiopacity label illustrated in first embodiment.
Disclosed embodiment of this invention is merely to illustrate and is not intended to limit technical idea of the invention, of the invention The range of technical idea is not limited by embodiment as described above.Guarantor of the invention should be explained based on claims Range is protected, should be construed as, it is of the invention in that should all be included in all technical ideas in claim equivalency range In interest field.

Claims (9)

1. a kind of medicine released biological degradability bracket characterized by comprising
First support structural body is braided by specific pattern on fixture by the wire of marmem material and is formed, And there are multiple cells according to the silk cross-modality on braiding structure and be configured as hollow tubular；And
Second support structural body is shape using the printing material progress 3D printing comprising biodegradation high molecular and drug At 3D printing object, the 3D printing object has and multiple cells and is configured as according to the silk cross-modality in print structure Hollow tubular, and the second support structural body is arranged to cover the outer peripheral surface or described of the first support structural body The outer peripheral surface of second support structural body is covered by the first support structural body.
2. a kind of medicine released biological degradability bracket characterized by comprising
First support structural body is braided by specific pattern on fixture by the wire of marmem material and is formed, And there are multiple cells according to the silk cross-modality on braiding structure and be configured as hollow tubular；
Second support structural body is equivalent to and carries out 3D printing using the printing material comprising biodegradation high molecular and drug And the 3D printing object formed, the 3D printing object have multiple cells according to the silk cross-modality in print structure and are matched It is set to hollow tubular；And
Third supporting structure body, is braided by specific pattern on fixture by the wire of marmem material and is formed, And there are multiple cells according to the silk cross-modality on braiding structure and be configured as hollow tubular, and be arranged to cover The outer peripheral surface of the first support structural body or the outer peripheral surface of the third supporting structure body are covered by the first support structure Body covering,
The second support structural body insertion is set to the sky between the first support structural body and third supporting structure body Between.
3. such as claim 1 or medicine released biological degradability bracket as claimed in claim 2, which is characterized in that
The second support structural body is after 3D printing by utilizing the coating for being mixed with biodegradation high molecular and drug Coating processing process on the surface of mixture is formed with the coat comprising drug on surface.
4. medicine released biological degradability bracket as claimed in claim 3, which is characterized in that
In order to by 3D printing be equipped in the printing material that the second support structural body utilizes biodegradation high molecular with Biology in the application of mixture utilized to be equipped with the coat of the stacking coated on second support structural body surface More than one in the mutual type of degradable polymer and composition ratio is different, so that in order to by described in 3D printing outfit Second support structural body and the biodegradation period ratio of biodegradation high molecular is in the printing material that utilizes in order to be equipped with stacking The coat coated on second support structural body surface and biological degradability high score in the application of mixture that is utilized The biodegradation period of son is long.
5. medicine released biological degradability bracket as claimed in claim 3, which is characterized in that
It is laminated to be equipped with drug in the printing material that the second support structural body utilizes by 3D printing in order to be equipped with The coat coated on second support structural body surface and drug utilization identical type in the application of mixture that utilizes Drug be equipped with.
6. medicine released biological degradability bracket as described in claim 1, which is characterized in that
The first support structural body includes:
First main part is formed as hollow tubular；
First expansion tube department is formed in one end of first main part with the diameter compared to first main part extension；And
Second expansion tube department is formed in the other end of first main part with the diameter compared to first main part extension,
The second support structural body is provided as the length with the length less than or equal to first main part, and is arranged Outer peripheral surface for the outer peripheral surface or the second support structural body that cover first main part is covered by the main part.
7. medicine released biological degradability bracket as claimed in claim 6, which is characterized in that further include:
Multiple radiopacity label, are arranged in the multiple regions on the first support structural body, to ensure to be arranged in body The visuality of interior bracket,
More than two rays of the both ends side for being set to the main part in the multiple radiopacity label are not Permeability label is arranged to for the both ends of the second support structural body to be fixedly attached to the form of the main part.
8. medicine released biological degradability bracket as claimed in claim 2, it is characterised in that
The first support structural body includes:
First main part is formed as hollow tubular；
First expansion tube department is formed in one end of first main part with the diameter compared to first main part extension；And
Second expansion tube department is formed in the other end of first main part with the diameter compared to first main part extension,
The third supporting structure body includes:
Second main part is formed as hollow tubular；
Third expansion tube department is formed in one end of second main part with the diameter compared to second main part extension；And
4th expansion tube department is formed in the other end of second main part with the diameter compared to second main part extension,
The second support structural body is provided as with less than or equal to first main part and second main part The length of length, and be inserted into and be set between first main part and second main part.
9. medicine released biological degradability bracket as claimed in claim 8, it is characterised in that
In the side of first support structural body and third supporting structure body, by first expansion tube department and third expansion tube department and The bound fraction that second expansion tube department and the 4th expansion tube department are formed as one respectively is provided as more than one by each region, the The second support structural body is inserted between one supporting structure body and third supporting structure body.
CN201680088648.6A 2016-08-24 2016-11-01 Drug-releasing biodegradable stent Active CN109688983B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020160107551A KR101821746B1 (en) 2016-08-24 2016-08-24 Drug eluting type biodegradable stent
KR10-2016-0107551 2016-08-24
PCT/KR2016/012465 WO2018038318A1 (en) 2016-08-24 2016-11-01 Drug-releasing biodegradable stent

Publications (2)

Publication Number Publication Date
CN109688983A true CN109688983A (en) 2019-04-26
CN109688983B CN109688983B (en) 2021-04-23

Family

ID=57540385

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680088648.6A Active CN109688983B (en) 2016-08-24 2016-11-01 Drug-releasing biodegradable stent

Country Status (7)

Country Link
US (1) US10932928B2 (en)
EP (1) EP3505141B1 (en)
JP (1) JP6784830B2 (en)
KR (1) KR101821746B1 (en)
CN (1) CN109688983B (en)
ES (1) ES2896324T3 (en)
WO (1) WO2018038318A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113234209A (en) * 2021-05-28 2021-08-10 大连大学 Method for initiating lactide ring-opening dispersion polymerization by luteolin in supercritical carbon dioxide
CN115500991A (en) * 2022-07-26 2022-12-23 柏为（武汉）医疗科技股份有限公司 Ear-nose cavity support and support conveying device

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101905687B1 (en) * 2017-01-17 2018-10-11 포항공과대학교 산학협력단 Stent Having Multiple Layer Structure and Its Manufacturing Method
WO2018163055A1 (en) * 2017-03-06 2018-09-13 Cardiovascular Lab S.P.A. O Brevemente Cv Lab S.P.A. Multilayer luminal endoprosthesis and manufacturing method
CN107095701A (en) * 2017-05-23 2017-08-29 上海英诺伟医疗器械有限公司 A kind of closure basket and the plugging device with the basket
CN111760179A (en) * 2020-06-30 2020-10-13 南方科技大学 External vascular stent and application thereof

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693085A (en) * 1994-04-29 1997-12-02 Scimed Life Systems, Inc. Stent with collagen
US6193746B1 (en) * 1992-07-08 2001-02-27 Ernst Peter Strecker Endoprosthesis that can be percutaneously implanted in the patient's body
US20060147612A1 (en) * 2002-11-21 2006-07-06 Ronaldo Da Rocha Loures Endoprosthesis process to obtain and methods used
CN101496754A (en) * 2008-01-29 2009-08-05 太雄医疗器株式会社 Biodegradable double stent
CN101626800A (en) * 2007-03-14 2010-01-13 S&G生技股份有限公司 Stent for expending intra luminal
US20130331927A1 (en) * 2007-01-19 2013-12-12 Elixir Medical Corporation Biodegradable endoprosthesis and methods for their fabrication
CN103568326A (en) * 2012-07-30 2014-02-12 比亚迪股份有限公司 Preparation method of intravascular stent, and intravascular stent prepared thereby
US20140121759A1 (en) * 2012-10-31 2014-05-01 W. L. Gore & Associates, Inc. Post-implantation contractible or expandable devices and method of using and making the same
CN104487024A (en) * 2012-03-16 2015-04-01 麦克柔文绅有限公司 Stent and stent delivery device
US20150094796A1 (en) * 2012-10-08 2015-04-02 Cormatrix Cardiovascular, Inc. Reinforced Vascular Prostheses
CN204542477U (en) * 2015-02-10 2015-08-12 东莞颠覆产品设计有限公司 The expansible intravascular stent of a kind of multilamellar
US20150283308A1 (en) * 2014-04-03 2015-10-08 Cook Biotech, Incorporated Endoluminal device and method of implanting same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8021418B2 (en) * 2003-06-19 2011-09-20 Boston Scientific Scimed, Inc. Sandwiched radiopaque marker on covered stent
GB0524110D0 (en) * 2005-11-28 2006-01-04 Univ Cambridge Tech Biomarkers and methods for identification of agents useful in the treatment of affective disorders
KR101006984B1 (en) * 2008-10-23 2011-01-12 신경민 A Double Stent
US20090192588A1 (en) * 2008-01-29 2009-07-30 Taeoong Medical Co., Ltd Biodegradable double stent
US7815673B2 (en) * 2008-04-01 2010-10-19 Medtronic Vascular, Inc. Double-walled stent system
US8784473B2 (en) * 2009-09-10 2014-07-22 Boston Scientific Scimed, Inc. Endoprosthesis with filament repositioning or retrieval member and guard structure
WO2012011269A1 (en) 2010-07-20 2012-01-26 株式会社 京都医療設計 Stent cover member and stent device
KR101262931B1 (en) 2011-01-13 2013-05-09 전남대학교산학협력단 Drug release controllable multi-layer coating stent and method for preparing the same
KR101244416B1 (en) * 2011-02-28 2013-03-18 부산대학교 산학협력단 stent with triple coaxial structure
EP2740439B1 (en) * 2012-12-10 2018-10-31 Abbott Laboratories Vascular Enterprises Limited Stent graft having two coaxial stents and a graft tissue
KR101467102B1 (en) 2013-06-20 2014-12-01 아주대학교산학협력단 Multi-layered structure for drug reservoir and drug eluting stent including the same
KR101650514B1 (en) 2014-06-19 2016-08-23 주식회사 엠아이텍 Hybrid Vascular Stent
KR101519922B1 (en) * 2014-07-21 2015-05-14 한국기계연구원 Drug eluting stent and manufacturing method thereof
EP3247316B1 (en) 2015-01-20 2024-03-06 Monarch Biosciences, Inc. Self-expandable scaffolding device for the treatment of aneurysms
US20180117219A1 (en) * 2015-04-29 2018-05-03 Northwestern University 3d printing of biomedical implants

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6193746B1 (en) * 1992-07-08 2001-02-27 Ernst Peter Strecker Endoprosthesis that can be percutaneously implanted in the patient's body
US5693085A (en) * 1994-04-29 1997-12-02 Scimed Life Systems, Inc. Stent with collagen
US20060147612A1 (en) * 2002-11-21 2006-07-06 Ronaldo Da Rocha Loures Endoprosthesis process to obtain and methods used
US20130331927A1 (en) * 2007-01-19 2013-12-12 Elixir Medical Corporation Biodegradable endoprosthesis and methods for their fabrication
CN101626800A (en) * 2007-03-14 2010-01-13 S&G生技股份有限公司 Stent for expending intra luminal
CN101496754A (en) * 2008-01-29 2009-08-05 太雄医疗器株式会社 Biodegradable double stent
CN104487024A (en) * 2012-03-16 2015-04-01 麦克柔文绅有限公司 Stent and stent delivery device
CN103568326A (en) * 2012-07-30 2014-02-12 比亚迪股份有限公司 Preparation method of intravascular stent, and intravascular stent prepared thereby
US20150094796A1 (en) * 2012-10-08 2015-04-02 Cormatrix Cardiovascular, Inc. Reinforced Vascular Prostheses
US20140121759A1 (en) * 2012-10-31 2014-05-01 W. L. Gore & Associates, Inc. Post-implantation contractible or expandable devices and method of using and making the same
US20150283308A1 (en) * 2014-04-03 2015-10-08 Cook Biotech, Incorporated Endoluminal device and method of implanting same
CN204542477U (en) * 2015-02-10 2015-08-12 东莞颠覆产品设计有限公司 The expansible intravascular stent of a kind of multilamellar

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113234209A (en) * 2021-05-28 2021-08-10 大连大学 Method for initiating lactide ring-opening dispersion polymerization by luteolin in supercritical carbon dioxide
CN115500991A (en) * 2022-07-26 2022-12-23 柏为（武汉）医疗科技股份有限公司 Ear-nose cavity support and support conveying device

Also Published As

Publication number Publication date
JP2019528119A (en) 2019-10-10
WO2018038318A1 (en) 2018-03-01
EP3505141B1 (en) 2021-10-13
US20190183667A1 (en) 2019-06-20
CN109688983B (en) 2021-04-23
EP3505141A4 (en) 2020-03-18
JP6784830B2 (en) 2020-11-11
EP3505141A1 (en) 2019-07-03
US10932928B2 (en) 2021-03-02
KR20160133387A (en) 2016-11-22
ES2896324T3 (en) 2022-02-24
KR101821746B1 (en) 2018-01-24

Similar Documents

Publication Publication Date Title
CN109688983A (en) Medicine released biological degradability bracket
JP5796911B2 (en) Temporary stiffening mesh prosthesis
AU2003286631B2 (en) Intraluminal prostheses and carbon dioxide-assisted methods of impregnating same with pharmacological agents
CN103764076B (en) Biodegradable built-in prothesis and its manufacture method
KR102035878B1 (en) Eluting medical devices
CN103930074B (en) A kind of particular design of biodegradable drug stent
JP2012016593A (en) Self-detachable medical device
US20140212355A1 (en) Trans-arterial drug delivery
CN102245132A (en) Bioabsorbable polymeric medical device
KR101822487B1 (en) Drug storage in micropore type biodegradable stent
CN110201242A (en) A kind of medical device
CN105636616A (en) Dissolvable or degradable adhesive polymer to prevent stent migration
JP2011156355A (en) Differential loading of drug-eluting medical device
JP2021523236A (en) Implantable polymer depot for controlled release of therapeutic agent
DE102007034991A1 (en) Production of a stent, useful to treat stenosis and aneurism, comprises providing a catheter and a stent, coating the catheter on the surface with e.g. a polymer and positioning and crimping the stent on the surface of the catheter
US20040106988A1 (en) Resorbable prosthesis for medical treatment
KR101822486B1 (en) Drug releasing type hybrid stent
CN104524646A (en) Biodegradable drug eluting stent and manufacturing method thereof
KR20140057357A (en) Self-expandable biodegradable stent made of clad radiopaque fibers covered with biodegradable elastic foil and therapeutic agent and method of preparation thereof
Sah Overview of polylactide-co-glycolide drug delivery systems

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant